Recombinant Human IL-29/IFN-lambda 1

This lyophilized preparation is stable at 2-8C, but should be kept desiccated at -20C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-8C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -80C. Avoid repeated freeze/thaw cycles.

IL-28A, IL-28B, and IL-29, also named interferon-ƒE2 (IFN-ƒE2), IFN-ƒE3, and IFN-ƒE1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or doublestranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and upregulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 Rbeta) and a novel IL-28 receptor alpha (IL-28 Ralpha, also known as IFN-ƒER1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. Recombinant Human IL-29/IFN-lambda 1is a single non-glycosylated polypeptide chain containing 181 amino acids.

Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/mL. Further dilutions should be made in appropriate buffered solutions.

Fully biologically active. The ED50 determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml